首页> 美国卫生研究院文献>BMC Systems Biology >Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer
【2h】

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer

机译:共表达网络分析确定脾酪氨酸激酶(SYK)是小细胞肺癌子集中的候选致癌驱动因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundOncogenic mechanisms in small-cell lung cancer remain poorly understood leaving this tumor with the worst prognosis among all lung cancers. Unlike other cancer types, sequencing genomic approaches have been of limited success in small-cell lung cancer, i.e., no mutated oncogenes with potential driver characteristics have emerged, as it is the case for activating mutations of epidermal growth factor receptor in non-small-cell lung cancer. Differential gene expression analysis has also produced SCLC signatures with limited application, since they are generally not robust across datasets. Nonetheless, additional genomic approaches are warranted, due to the increasing availability of suitable small-cell lung cancer datasets. Gene co-expression network approaches are a recent and promising avenue, since they have been successful in identifying gene modules that drive phenotypic traits in several biological systems, including other cancer types.
机译:背景技术小细胞肺癌的致癌机制仍然知之甚少,使该肿瘤在所有肺癌中的预后最差。与其他类型的癌症不同,测序基因组方法在小细胞肺癌中取得的成功有限,即没有出现具有潜在驱动特性的突变癌基因,因为在非小细胞肺癌中激活表皮生长因子受体的突变就是这种情况。细胞肺癌。差异基因表达分析还产生了应用有限的SCLC签名,因为它们通常在整个数据集中都不可靠。但是,由于合适的小细胞肺癌数据集的可用性越来越高,因此需要其他基因组方法。基因共表达网络方法是一种新近且有前途的途径,因为它们已成功地鉴定出在包括其他癌症类型在内的几种生物系统中驱动表型性状的基因模块。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号